Quincy S. Chu

机构：University of Alberta · ORCID：0000-0003-4814-3126

发表论文 290 篇 · 总被引 7528 次 · h-index 41

代表论文

• Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC (2025 · Journal of Thoracic Oncology · 被引 7)
• MA03.03 SAVANNAH: Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and / or Amp NSCLC (2025 · Journal of Thoracic Oncology · 被引 2)
• Perioperative Durvalumab for Resectable Non–Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial (2026 · Journal of Clinical Oncology)
• Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced BRAF -mutant melanoma. (2026 · Journal of Clinical Oncology)
• PMH-001: A first-in-human phase I study of the novel microtubule disruptor CCI-001 in patients with advanced cancer. (2026 · Journal of Clinical Oncology)
• OA12.02 CCTG IND227, a Randomized Trial of Chemotherapy + Pembrolizumab in Advanced Pleural Mesothelioma: Updated Analyses (2025 · Journal of Thoracic Oncology)